Press Releases

    • NOV 13 2017

    Effectiveness of ONC201 in H3 K27M Glioma to be Presented at SNO

    Philadelphia, PA (November 13, 2017) – Oncoceutics, Inc. today announced that five clinical and preclinical presentations on ONC201 and ONC206 for the treatment of high grade gliomas will be presented at the 22nd Annual Scientific Meeting and Education Day of the Society of Neuro-Oncology, held November 16th-19th in San Francisco. The series of presentations describe

    • NOV 03 2017

    ONC201 Trial for Histone Mutant Glioma Begins at NYU

    Philadelphia, PA (November 3, 2017) – Oncoceutics, Inc. announced today that the first patient has been treated in a Phase II clinical trial of ONC201 for patients with recurrent high-grade gliomas that contain a specific mutation called the histone H3 K27M mutation. The trial is led by Andrew Chi, MD, PhD, Chief of Neuro-oncology and

    • OCT 09 2017

    Oncoceutics and MD Anderson Expand Alliance to Cover Imipridone ONC212

    Philadelphia, PA (October 9, 2017) – Oncoceutics Inc. and The University of Texas MD Anderson Cancer Center announced the expansion of their strategic alliance and research collaboration agreement to include the clinical development of ONC212. Since 2015, Oncoceutics and MD Anderson have collaborated on the clinical development of ONC201, the founding member of the imipridone

    • SEP 11 2017

    Oncoceutics Begins ONC201 Endometrial Cancer Trial; Receives NIH Grant

    Philadelphia, PA (September 11, 2017) – Oncoceutics, Inc. announced the launch of a clinical trial of ONC201 for patients with recurrent or metastatic endometrial cancer at the Fox Chase Cancer Center. The Phase II trial, being led by Gina Mantia-Smaldone, MD, Assistant Professor in the Department of Surgical Oncology, is listed on under NCT03099499